zuberitamab

Zuberitamab (HS006, trade name Anruixi) is a recombinant human-mouse chimeric IgG1 kappa monoclonal antibody targeting the B-lymphocyte antigen CD20 (MS4A1). Developed by BioRay Pharmaceutical (originally the biologics division of Zhejiang Hisun Pharmaceutical), zuberitamab binds to a distinct epitope on CD20 compared to rituximab, mediating potent B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In May 2023, the National Medical Products Administration (NMPA) of China approved zuberitamab for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL). It is also undergoing clinical evaluation for other B-cell malignancies, such as follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma, as well as autoimmune conditions including primary immune thrombocytopenia (ITP) and membranous nephropathy.

Brand names

AnruixiEnricixEnrexib

Other names

RHCACD20MARHCACD-20MARHCACD 20MArecombinant human-mouse chimeric anti-CD20 monoclonal antibodyrecombinant human-mouse chimeric anti-CD20 monoclonal antibody injectionzebetuzumab